Vanguard Group Inc. raised its stake in Fluidigm Co. (NASDAQ:FLDM) by 84.1% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 3,746,808 shares of the medical research company’s stock after purchasing an additional 1,711,187 shares during the quarter. Vanguard Group Inc. owned about 5.40% of Fluidigm worth $46,160,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds also recently made changes to their positions in the business. BlackRock Inc. boosted its holdings in shares of Fluidigm by 86.5% in the 2nd quarter. BlackRock Inc. now owns 4,943,298 shares of the medical research company’s stock valued at $60,902,000 after purchasing an additional 2,293,024 shares during the last quarter. Castleark Management LLC boosted its holdings in shares of Fluidigm by 12.2% in the 2nd quarter. Castleark Management LLC now owns 273,077 shares of the medical research company’s stock valued at $3,364,000 after purchasing an additional 29,695 shares during the last quarter. Northern Trust Corp boosted its holdings in shares of Fluidigm by 9.5% in the 2nd quarter. Northern Trust Corp now owns 536,942 shares of the medical research company’s stock valued at $6,616,000 after purchasing an additional 46,480 shares during the last quarter. Cadence Capital Management LLC boosted its holdings in shares of Fluidigm by 86.0% in the 2nd quarter. Cadence Capital Management LLC now owns 265,236 shares of the medical research company’s stock valued at $3,268,000 after purchasing an additional 122,674 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its holdings in shares of Fluidigm by 17.1% in the 2nd quarter. Renaissance Technologies LLC now owns 2,522,800 shares of the medical research company’s stock valued at $31,081,000 after purchasing an additional 367,718 shares during the last quarter.
In other Fluidigm news, Director Samuel D. Colella bought 9,000 shares of the business’s stock in a transaction dated Wednesday, August 7th. The shares were acquired at an average price of $7.00 per share, with a total value of $63,000.00. Following the purchase, the director now owns 115,481 shares in the company, valued at approximately $808,367. The purchase was disclosed in a document filed with the SEC, which is available through this link. Also, insider Levin Easterly Partners Llc sold 577,197 shares of Fluidigm stock in a transaction on Tuesday, September 17th. The stock was sold at an average price of $5.40, for a total transaction of $3,116,863.80. The disclosure for this sale can be found here. In the last three months, insiders bought 15,000 shares of company stock worth $95,460 and sold 1,456,923 shares worth $12,002,797. Company insiders own 2.00% of the company’s stock.
Shares of FLDM stock traded down $0.01 during mid-day trading on Monday, reaching $4.30. The company’s stock had a trading volume of 9,099 shares, compared to its average volume of 702,695. The company’s 50 day simple moving average is $5.19 and its 200-day simple moving average is $10.08. Fluidigm Co. has a 12-month low of $4.10 and a 12-month high of $14.90. The company has a quick ratio of 2.48, a current ratio of 2.86 and a debt-to-equity ratio of 0.32. The firm has a market capitalization of $291.13 million, a PE ratio of -5.39 and a beta of 2.33.
Fluidigm (NASDAQ:FLDM) last issued its earnings results on Thursday, August 1st. The medical research company reported ($0.20) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.12) by ($0.08). Fluidigm had a negative net margin of 57.48% and a negative return on equity of 31.45%. The business had revenue of $28.20 million during the quarter, compared to analysts’ expectations of $30.16 million. Fluidigm’s revenue was up 6.8% on a year-over-year basis. As a group, research analysts anticipate that Fluidigm Co. will post -0.55 EPS for the current fiscal year.
Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research in the United States and Europe. It offers analytical systems comprising Helios, a CyTOF system, Hyperion imaging system, and Hyperion tissue imager; and assays and reagents, including Maxpar reagents and Maxpar human immune monitoring panel kit and workflow.
Read More: What are catch-up contributions?
Want to see what other hedge funds are holding FLDM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Fluidigm Co. (NASDAQ:FLDM).
Receive News & Ratings for Fluidigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm and related companies with MarketBeat.com's FREE daily email newsletter.